N. Poitras

发表

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer

M. Schiffman, P. Castle, T. Lorey, 2018, Annals of Internal Medicine.

Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

M. Schiffman, N. Wentzensen, P. Castle, 2019, JAMA internal medicine.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

M. Schiffman, P. Castle, T. Raine-Bennett, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of a large biorepository of cervical specimens for the Improving Risk Informed HPV Screening study (IRIS).

M. Schiffman, T. Raine-Bennett, T. Lorey, 2021, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Variable Risk of Cervical Precancer and Cancer After a Human Papillomavirus–Positive Test

M. Schiffman, P. Castle, T. Lorey, 2011, Obstetrics and gynecology.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2017, Journal of lower genital tract disease.

The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics

Nicole E. Varnado, N. Wentzensen, P. Castle, 2021, Cancer Epidemiology, Biomarkers & Prevention.

A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting.

M. Schiffman, P. Castle, T. Lorey, 2013, Journal of virological methods.

The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.

M. Schiffman, N. Wentzensen, P. Castle, 2021, Gynecologic oncology.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

M. Schiffman, P. Castle, T. Lorey, 2017, Preventive medicine.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

M. Schiffman, P. Castle, T. Raine-Bennett, 2017, Journal of Clinical Microbiology.

Adherence Patterns to Extended Cervical Screening Intervals in Women Undergoing HPV and Cytology Cotesting

M. Schiffman, P. Castle, T. Lorey, 2017 .

Why does cervical cancer occur in a state-of-the-art screening program?

M. Schiffman, P. Castle, T. Lorey, 2017, Gynecologic oncology.

Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2020, Journal of lower genital tract disease.

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing

M. Schiffman, P. Castle, T. Raine-Bennett, 2018, Journal of Clinical Microbiology.

Safety against cervical precancer and cancer following negative human papillomavirus and Papanicolaou test results in human immunodeficiency virus-infected women.

P. Castle, T. Lorey, W. Kinney, 2012, Archives of internal medicine.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Mark Schiffman, Sholom Wacholder, Hormuzd A Katki, 2011, The Lancet. Oncology.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years

M. Schiffman, P. Castle, T. Lorey, 2018, Cancer Prevention Research.

Premature conclusions on HPV-only testing – Authors' reply

S. Wacholder, M. Schiffman, P. Castle, 2011 .

Lessons From Practice: Risk of CIN 3 or Cancer Associated With an LSIL or HPV-Positive ASC-US Screening Result in Women Aged 21 to 24

J. T. Cox, P. Castle, T. Lorey, 2010, Journal of lower genital tract disease.

A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs

M. Schiffman, P. Castle, T. Raine-Bennett, 2020, EClinicalMedicine.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy

M. Schiffman, N. Wentzensen, P. Castle, 2018, Journal of lower genital tract disease.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

M. Schiffman, P. Castle, T. Lorey, 2019, JAMA oncology.

A cohort study of cervical screening using partial HPV typing and cytology triage

M. Schiffman, P. Castle, T. Raine-Bennett, 2016, International journal of cancer.

Age‐stratified 5‐year risks of cervical precancer among women with enrollment and newly detected HPV infection

M. Schiffman, P. Castle, T. Lorey, 2015, International journal of cancer.

Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap Cotesting in Posttreatment Management

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Relationship of Atypical Glandular Cell Cytology, Age, and Human Papillomavirus Detection to Cervical and Endometrial Cancer Risks

P. Castle, T. Lorey, W. Kinney, 2010, Obstetrics and gynecology.

Human Papillomavirus (HPV) Genotypes in Women with Cervical Precancer and Cancer at Kaiser Permanente Northern California

M. Schiffman, P. Castle, T. Lorey, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting

M. Schiffman, P. Castle, T. Lorey, 2019, International journal of cancer.

Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting

P. Castle, T. Lorey, W. Kinney, 2009, Obstetrics and gynecology.

Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral‐host interaction with implications for disease intervention

M. Yeager, Kai Yu, L. Burdett, 2020, International journal of cancer.

The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer

P. Castle, T. Lorey, W. Kinney, 2010, Obstetrics and gynecology.

Follow-up Testing After Colposcopy: Five-Year Risk of CIN 2+ After a Colposcopic Diagnosis of CIN 1 or Less

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

M. Schiffman, P. Castle, T. Lorey, 2018, Journal of the National Cancer Institute.

The population impact of human papillomavirus/cytology cervical cotesting at 3‐year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen

M. Schiffman, P. Castle, T. Lorey, 2016, Cancer.

p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.

M. Schiffman, N. Wentzensen, P. Castle, 2015, Journal of the National Cancer Institute.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

M. Schiffman, P. Castle, T. Lorey, 2014, Journal of the National Cancer Institute.

Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice.

S. Wacholder, M. Schiffman, P. Castle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women

M. Schiffman, N. Wentzensen, P. Castle, 2018, Clinical Cancer Research.

Accuracy and Efficiency of Deep-Learning–Based Automation of Dual Stain Cytology in Cervical Cancer Screening

N. Grabe, M. Schiffman, N. Wentzensen, 2020, Journal of the National Cancer Institute.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening

M. Schiffman, P. Castle, T. Lorey, 2018, Journal of the National Cancer Institute.

A general binomial regression model to estimate standardized risk differences from binary response data

R. Varadhan, S. Wacholder, S. Kovalchik, 2013, Statistics in medicine.

Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Risk of Cervical Precancer and Cancer in Women Aged 30 Years and Older With an HPV-Negative Low-Grade Squamous Intraepithelial Lesion Screening Result

J. T. Cox, P. Castle, T. Lorey, 2011, Journal of lower genital tract disease.

The low risk of precancer after a screening result of human papillomavirus‐negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management

J. Cuzick, M. Schiffman, P. Castle, 2014, Cancer cytopathology.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

M. Schiffman, P. Castle, T. Lorey, 2018, Preventive medicine.

Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.

M. Schiffman, P. Castle, T. Lorey, 2019, Preventive medicine.

A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2020, Journal of lower genital tract disease.

Interobserver reproducibility and accuracy of p16/Ki‐67 dual‐stain cytology in cervical cancer screening

M. Schiffman, N. Wentzensen, P. Castle, 2014, Cancer cytopathology.

Invasive Cervical Cancer After a Positive Pap Test Result and Negative Human Papillomavirus Test Result.

P. Castle, T. Lorey, N. Wentzensen, 2021, Obstetrics and gynecology.

Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Screening history preceding a diagnosis of cervical cancer in women age 65 and older.

J. T. Cox, P. Castle, T. Lorey, 2012, Gynecologic oncology.

Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus–Positive Screening Test Results

Kanan T. Desai, Xin He, M. Schiffman, 2022, Journal of lower genital tract disease.

A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15‐year cervical cancer screening experience at Kaiser Permanente Northern California

M. Schiffman, P. Castle, T. Lorey, 2020, International journal of cancer.

Cervical Cancer Rates After the Transition From Annual Pap to 3-Year HPV and Pap

P. Castle, T. Lorey, H. Dinkelspiel, 2014, Journal of lower genital tract disease.

Erratum: The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer (Obstet Gynecol (2010) 116 (76-84))

P. Castle, T. Lorey, W. Kinney, 2010 .

Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology

R. E. Stamps, Kai Yu, W. Wheeler, 2018, Journal of the National Cancer Institute.

Risk of Cervical Precancer and Cancer in Women With Cervical Intraepithelial Neoplasia Grade 1 on Endocervical Curettage

T. Lorey, W. Kinney, B. Fetterman, 2013, Journal of lower genital tract disease.

Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.

P. Castle, T. Lorey, N. Wentzensen, 2024, Gynecologic oncology.

The population impact of human papillomavirus/cytology cervical cotesting at 3‐year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen

M. Schiffman, P. Castle, T. Lorey, 2016, Cancer.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

S. Wacholder, M. Schiffman, P. Castle, 2011, The Lancet. Oncology.